Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit
CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...
Read More
Dividend/Distribution – CUV
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
Appendix 4E & Annual Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
CLINUVEL Communiqué IV
Melbourne, Australia, 23 August 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
PRÉNUMBRA® for stroke
Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
CLINUVEL Kommuniqué III
Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL Communiqué III
Since News Communiqué II on 31 March 2022, the Company has reported...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Jeffries Healthcare Conference June 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the Jeffries Healthcare...
Read More
H.C. Wainwright Global Investment Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
Notice of change of interests of initial substantial holder
Melbourne, Australia, 25 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More